Phosphagenics Announces Initiation Of Phase 1 Clinical Trial In Humans For Its Transdermal Lidocaine
Medical News Today (Free subscription) | 24/09/2008
Phosphagenics Limited ("Phosphagenics") (ASX: POH; AIM: PSG; OTCQX: PPGNY) announced that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading pain relief drug, lidocaine.















